HSBC analyst Rajesh Kumar initiated coverage of Danaher with a Hold rating. The year of U.S. elections “often can be a source of angst for Biopharma investors,” says the firm, which thinks 2024 will see a heated debate on the impact of drug pricing on the Biopharma industry’s earnings power. In addition, capital allocation and growth beyond patent cliffs is “the second big question the market might have to grapple with is around,” the analyst said in a sector note on Biopharma’s key debates for 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DHR:
- Codexis and Aldevron in licensing pact for Codex HiCap RNA Polymerase
- Danaher initiated with neutral view at Wolfe Research, here’s why
- Danaher initiated with neutral view at Wolfe Research
- Danaher price target raised by $15 at Citi, here’s why
- Biogen upgraded, Take-Two downgraded: Wall Street’s top analyst calls
